| 7.96 Data as of May 17 |  -0.02 / -0.25%Today’s Change | 3.86 Today|||52-Week Range 9.92 | +18.63% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $900.8M |
Halozyme Therapeutics, Inc. 11388 Sorrento Valley Road San Diego California 92121-1345 |
| Mutual fund holders | 26.32% |
| Individual stakeholders | 24.16% |
| Other institutional | 20.07% |
| Gregory Ian Frost, PhD | President, Chief Executive Officer & Director |
| William J. Fallon, PhD | Vice President-Manufacturing & Operations |
| Kurt A. Gustafson, MBA | Chief Financial Officer & Vice President |
| Douglas B. Muchmore, MD | Vice President-Endocrinology Clinical Development |
| H. Michael Shepard, PhD | Chief Scientific Officer & Vice President |
.
